A Medical Device Daily
Ambry Genetics (San Diego) and RainDance Technologies (Lexington, Massachusetts) jointly reported their partnership using the RDT 1000 for sequence enrichment and resequencing validation. Ambry Genetics is a CLIA certified and CAP accredited diagnostic and genomic services company providing solutions to both clinical and research clients.
“Ambry Genetics has dedicated its investments in technology for the benefit of the scientific and research community,“ said Ardy Arianpour, director of business development. “The addition of RainDance's RDT 1000 adds a sequence-enrichment offering while providing an option for customers that are in need of high-throughput targeted sequencing with a high level of coverage, completeness and speed.“
Researchers can utilize the RDT 1000 and Ambry Genetics Next Generation Services to either reduce study time, or to improve study quality by running more samples in the same time within the same experimental budget.
In other agreements/contracts news:
• Acacia Research (Newport Beach California) reported that its Medical Monitoring and Paging subsidiary has entered into a license agreement with General Electric (Schenectady, New York) covering a patent directed to medical monitoring and paging technology. This agreement resolves the parties' dispute that was pending in the District Court for the Southern District of Texas.
• Premier Purchasing Partners (Charlotte, North Carolina) reported that new agreements for laparoscopic surgical instruments have been awarded to Aesculap (Center Valley, Pennsylvania), CareFusion (San Diego), Genicon (Winter Park, Florida), Jarit Surgical Instruments (Hawthorne, New York), National Advance Endoscopy Devices (Canoga Park, California) and Surgical Innovations (Virginia Beach, Virginia). Effective February 1, 2010, the agreements are available to acute care and continuum of care members of the Premier healthcare alliance.
• Enzo Biochem (New York) reported a supply and distribution agreement between Enzo Life Sciences and Cancer Genetics (CGI; Rutherford, New Jersey). This agreement covers Enzo's proprietary fluorescent dye labels for increasing signal intensity in labeling nucleic acids.
The non-exclusive agreement enables Enzo Life Sciences to incorporate its proprietary labeling to increase specificity for CGI's nucleic acid material that it purchases and supplies to the research market. The Enzo labeling in essence affords the CGI probe greater visual sensitivity and the potential for improved clinical value and patient outcomes.